8-K: NeuroBo's DA-1726 Shows Superior Results in Pre-Clinical Trials Compared to Survodutide and Tirzepatide

NeuroBo Pharmaceuticals' DA-1726 demonstrated superior weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide in pre-clinical models, with additional data showing superior cholesterol suppression compared to tirzepatide.

Summary

• NeuroBo Pharmaceuticals announced pre-clinical data for their drug candidate DA-1726, a dual agonist targeting GLP-1 and glucagon receptors.
• The data indicates that DA-1726 showed superior weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide in pre-clinical models.
• In obese mouse models, DA-1726 significantly lowered cholesterol levels and induced superior weight loss compared to survodutide.
• DA-1726 also demonstrated superior glucose lowering compared to survodutide.
• In a hypercholesterolemia rat model, DA-1726 was more effective than tirzepatide in suppressing cholesterol levels.
• The Phase 1 trial of DA-1726 is progressing well, with top-line data from the single ascending dose (SAD) Part 1 expected in the third quarter of this year and top-line data from the multiple ascending dose (MAD) Part 2 expected in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive pre-clinical results for DA-1726, suggesting a potential breakthrough in obesity treatment. The comparison to existing drugs like survodutide and tirzepatide is favorable, and the Phase 1 trial is progressing well. However, it is still early stage and there are risks associated with clinical trials and regulatory approvals.

Positives

• DA-1726 has shown superior weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide in pre-clinical models.
• DA-1726 demonstrated superior glucose lowering compared to survodutide.
• DA-1726 was more effective than tirzepatide in suppressing cholesterol levels in a hypercholesterolemia rat model.
• The Phase 1 trial of DA-1726 is progressing well.
• DA-1726 has a well understood mechanism of action as a dual agonist of GLP-1 and glucagon receptors.

Risks

• The results are based on pre-clinical models and may not translate directly to human clinical trials.
• The success of the Phase 1 trial is not guaranteed, and there may be delays or unexpected results.
• There are risks associated with the ability to obtain regulatory approval for DA-1726.
• There are risks associated with the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd.

Future Outlook

The company expects to dose the first patient in the multiple ascending dose (MAD) Part 2 and read-out top-line data from the single ascending dose (SAD) Part 1 of the Phase 1 trial in the third quarter of 2024, with top-line data from the MAD Part 2 expected in the first quarter of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the data being presented at the ADA further differentiates DA-1726 from obesity drugs in the same class, potentially due to its GLP-1 and glucagon receptor activity ratio.
• The company believes these distinguishing factors can potentially position DA-1726 as a best-in-class obesity drug with superior efficacy and better tolerability profile.

Industry Context

The announcement is significant in the context of the competitive obesity drug market, where companies are striving to develop more effective and tolerable treatments. DA-1726's dual-agonist approach and superior pre-clinical results position it as a potential contender in this space.

Comparison to Industry Standards

• The document compares DA-1726 to survodutide, a drug with the same mechanism of action, and tirzepatide, a drug with a similar mechanism of action.
• DA-1726 demonstrated superior weight loss, fat mass reduction, and glucose lowering compared to survodutide in pre-clinical models.
• DA-1726 was more effective than tirzepatide in suppressing cholesterol levels in a hypercholesterolemia rat model.
• These results suggest that DA-1726 may have a competitive advantage over existing treatments in the same class.

Stakeholder Impact

• Shareholders may react positively to the promising pre-clinical data.
• Employees may be motivated by the progress of DA-1726.
• Customers (potential patients) may benefit from a new and potentially more effective obesity treatment.
• Suppliers and creditors may see increased business opportunities if the drug progresses successfully.

Next Steps

• The company will continue the Phase 1 clinical trial of DA-1726.
• The company expects to dose the first patient in the multiple ascending dose (MAD) Part 2 in the third quarter of 2024.
• The company expects to read-out top-line data from the single ascending dose (SAD) Part 1 in the third quarter of 2024.
• The company expects to read-out top-line data from the multiple ascending dose (MAD) Part 2 in the first quarter of 2025.

Key Dates

Keywords

DA-1726, obesity, weight loss, lipid-lowering, survodutide, tirzepatide, GLP-1, glucagon, pre-clinical, clinical trial, cardiometabolic, MASH